Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 9

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Restoration of conformation of mutant p53

Green, J.A., Von Euler, M., Abrahmsen, L.B.·2018·Annals of Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy057

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 37

  1. Cordani, 2016, Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: involvement in cancer invasion and metastasis, Cancer Lett, 376, 303, 10.1016/j.canlet.2016.03.046 · DOI
  2. Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
  3. Bisio, 2014, TP53 mutants in the tower of babel of cancer progression, Hum Mutat, 35, 10.1002/humu.22514 · DOI
  4. Jackson, 2013, The mutant p53 mouse as a pre-clinical model, Oncogene, 32, 4325, 10.1038/onc.2012.610 · DOI
  5. Kaar, 2010, Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding, Protein Sci, 19, 2267, 10.1002/pro.507 · DOI · Paper page
  6. Demma, 2010, SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain, restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of HDM2-mediated ubiquitination of wild-type p53, J Biol Chem, 285, 10198, 10.1074/jbc.M109.083469 · DOI
  7. Rippin, 2002, Characterization of the p53-rescue drug CP-31398 in vitro and in living cells, Oncogene, 21, 2119, 10.1038/sj.onc.1205362 · DOI · Paper page
  8. Zache, 2008, Mutant p53 targeting by the low molecular weight compound STIMA-1, Mol Oncol, 2, 70, 10.1016/j.molonc.2008.02.004 · DOI · Paper page
  9. Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
  10. Jung, 2016, Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo, Oncotarget, 7, 77664, 10.18632/oncotarget.12758 · DOI
  11. Rökaeus, 2010, PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73, Oncogene, 29, 6442, 10.1038/onc.2010.382 · DOI
  12. Bykov, 2014, Mutant p53 reactivation by small molecules makes its way to the clinic, FEBS Lett, 588, 2622, 10.1016/j.febslet.2014.04.017 · DOI · Paper page
  13. Liu, 2015, APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma, Gut, 64, 1506, 10.1136/gutjnl-2015-309770 · DOI
  14. Supiot, 2008, PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status, Radiother Oncol, 86, 407, 10.1016/j.radonc.2008.01.001 · DOI
  15. The Cancer Genome Atlas Research Network, 2011, Integrated genomic analysis of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
  16. Basu, 2016, Pisarro: a phase 1b study of APR-246 with carboplatin and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer, Annal Oncol, 27, 386
  17. Salim, 2016, COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo, Oncotarget, 7, 41363, 10.18632/oncotarget.9133 · DOI · Paper page
  18. Puca, 2011, Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs, Cell Cycle, 10, 1679, 10.4161/cc.10.10.15642 · DOI
  19. Garufi, 2014, Degradation of mutant p53H175 protein by Zn(II) through autophagy, Cell Death Dis, 5, e1271, 10.1038/cddis.2014.217 · DOI
  20. Blanden, 2015, Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore, Mol Pharmacol, 87, 825, 10.1124/mol.114.097550 · DOI · Paper page
  21. Nelson, 2017, The essential medicinal chemistry of curcumin, J Med Chem, 60, 1620, 10.1021/acs.jmedchem.6b00975 · DOI · Paper page
  22. Lu, 2008, Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73, Cancer Biol Ther, 7, 2039, 10.4161/cbt.7.12.7461 · DOI
  23. Hong, 2014, Prodigiosin rescues deficient p53 signaling and antitumour effects via upregulating p73 and disrupting its interaction with mutant p53, Cancer Res, 74, 1153, 10.1158/0008-5472.CAN-13-0955 · DOI
  24. Mohell, 2015, APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells, Cell Death Dis, 6, e1794, 10.1038/cddis.2015.143 · DOI · Paper page
  25. Deben, 2016, APR-246 (PRIMA-1MET) strongly synergizes with AZD 2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines, Cancer Lett, 375, 313, 10.1016/j.canlet.2016.03.017 · DOI
  26. Yang-Hartwich, 2015, p53 protein aggregation promotes platinum resistance in ovarian cancer, Oncogene, 34, 3605, 10.1038/onc.2014.296 · DOI
  27. Xu, 2011, Gain of function of mutant p53 by co-aggregation with multiple tumor suppressors, Nat Chem Biol, 7, 285, 10.1038/nchembio.546 · DOI · Paper page
  28. Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
  29. Wang, 2016, Hsp90 inhibitor ganetespib sensitizes non-small cell lung cancer to radiation but has variable effects with chemoradiation, Clin Cancer Res, 22, 5876, 10.1158/1078-0432.CCR-15-2190 · doi:10.1158/1078-0432.ccr-15-2190
  30. Ramalingam, 2015, A randomized phase 2 study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second line non-small-cell lung cancer (GALAXY-1), Ann Oncol, 26, 1741, 10.1093/annonc/mdv220 · DOI
  31. Kumar, 2011, Kevetrin activates p53, enhances expression of p21 induces cell cycle arrest and apoptosis in a human cancer cell line, Cancer Res, 71
  32. Kumar, 2017, Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies, Cancer Res, 77
  33. Tamborero, 2013, Comprehensive identification of mutational cancer driver genes across 12 tumour types, Sci Rep, 3, 2650, 10.1038/srep02650 · DOI · Paper page
  34. Malkin, 2011, Li-Fraumeni syndrome, Genes Cancer, 2, 475, 10.1177/1947601911413466 · DOI · Paper page
  35. Purvis, 2012, p53 dynamics control cell fate, Science, 336, 1440, 10.1126/science.1218351 · DOI · Paper page
  36. Quartuccio, 2015, Mutant p53 expression in fallopian tube epithelium drives cell migration, Int J Cancer, 137, 1528, 10.1002/ijc.29528 · DOI
  37. Wu, 2013, Type I to Type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer, Am J Pathol, 182, 1391, 10.1016/j.ajpath.2012.12.031 · DOI

Cited by

See all 9

Metadata

Authors
Green, J. A., Von Euler, M., & Abrahmsen, L. B.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-05
Volume
29
Issue
5
Pages
1325-1328
ISSN
0923-7534
Cited by
9
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Restoration of conformation of mutant p53. https://app.cochat.ai/papers/10.1093/annonc/mdy057
The paper
Green, J. A., Von Euler, M., & Abrahmsen, L. B. (2018). Restoration of conformation of mutant p53. Annals of Oncology. https://doi.org/10.1093/annonc/mdy057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.